# Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

> **NCT00251407** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 46 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Taxotere
- **DRUG:** Cisplatin
- **DRUG:** CPT-11

## Key facts

- **NCT ID:** NCT00251407
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2003-01
- **Final completion:** 2009-04
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2012-08-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251407, "Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00251407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*